Amplia opens new front in ovarian cancer fight
Amplia Therapeutics has finalised plans for its PRROSE phase two ovarian cancer trial, with site activation and patient recruitment targeted before year-end.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.smh.com.au — the content belongs to Sydney Morning Herald - Business.
